个人情况介绍、概览

李季，男，博士，特聘副教授。2016年毕业于沈阳药科大学药物制剂专业，2019年于沈阳药科大学获药剂学硕士学位，2022年于同校获中药学博士学位，同年留校任教，被聘为沈阳药科大学特聘副教授。作为课题负责人主持国家自然科学基金青年项目1项、辽宁省教育厅项目1项、沈阳药科大学高层次人才引进科研启动项目1项、企业技术服务项目2项。目前，以第一或通讯作者身份在Acta Pharmaceutica Sinica B、Journal of Controlled Release、ACS Applied Materilas & Interfaces等领域知名期刊发表SCI论文10余篇。

人才称号、社会兼职等

沈阳市高层次人才

主要研究方向

研究方向一：肿瘤免疫治疗研究

研究方向二：组织微环境响应型药用材料的设计与核酸分子递送研究

研究方向三：基于制剂新技术、新理论的药物改良型新药设计研究

主持、参与的科研项目（含科研获奖等情况）

1.结合CRISPR/Cas9技术调控肿瘤代谢重编程与氧化还原稳态的仿生纳米载药系统的构建及其HNSCC精准治疗研究，国家自然科学基金青年项目，基金编号82304425（负责人）

2.基于代谢重编程与氧化还原失衡策略的头颈部鳞状细胞癌治疗研究，辽宁省教育厅基本科研项目，基金编号JYTQN2023321（负责人）

3.沈阳药科大学高层次人才引进科研启动项目（负责人）

4.次氯酸凝胶实验室小试处方工艺研究，企业技术服务项目（负责人）

5.中药CD238乳膏实验室小试处方工艺研究，企业技术服务项目（负责人）

近年来发表代表性论文(限第一作者或通讯作者，SCI须写明影响因子)：

1.Yuyi Xu^#; Ming Zhao^#; Jinxue Cao; Ting Fang; Jian Zhang; Yanli Zhen; Fangling Wu; Xiaohui Yu; Yaming Liu;Ji Li*; Dongkai Wang*; Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis, Acta Pharmaceutica Sinica B,2023,13(11): 4417-4441.(IF=14.5)

2.Ming Zhao^#;Ji Li^#; Fan Chen; Yanyan Han; Dawei Chen*; Haiyang Hu*; Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation, Journal of Controlled Release,2023, 355: 211-227.(IF=10.8)

3.Hongyu Yang^#; Ming Zhao^#, Dandan Xing; Jian Zhang; Ting Fang; Faxing Zhang; Zhihao Nie; Yaming Liu; Lihua Yang;Ji Li*; Dongkai Wang*; Contact lens as an emerging platform for ophthalmic drug delivery: A systematic review, Asian journal of pharmaceutical sciences,2023, 18(5): 100847.(IF=10.2)

4.Wendi Liang; Yingzhen Fan; Yinghui Liu; Ting Fang; Jian Zhang; Yuyi Xu;Ji Li*; Dongkai Wang*; ROS/pH dual-sensitive emodin-chlorambucil co-loaded micelles enhance anti-tumor effect through combining oxidative damage and chemotherapy, International Journal of Pharmaceutics,2023, 647: 123537.(IF=5.8)

5.Ji Li^#; Ming Zhao^#; Wendi Liang; Siwen Wu; Zheran Wang*; Dongkai Wang*; Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy, Journal of Controlled Release,2022, 342: 308-320.(IF=10.8)

6.Yang Sui^#; Ji Li^#; Jiqiang Qu; Ting Fang; Hongyan Zhang; Jian Zhang; Zheran Wang*; Mingyu Xia*; Yinghui Dai*; Dongkai Wang*; Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy, Asian Journal of Pharmaceutical Sciences,2022, 17(4): 583-595.(IF=10.2)

7.Ming Zhao^#;Ji Li^#; Jingwen Liu; Moxi Xu; Hongrui Ji; Siwen Wu; Dawei Chen*; Haiyang Hu*; Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction, Journal of Controlled Release,2021, 335: 320-332.(IF=11.467)

8.Ji Li^#; Ming Zhao^#; Yunhua Xu; Xiaoyun Hu; Yinghui Dai*; Dongkai Wang*; Hybrid micelles codelivering shikonin and IDO-1 siRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment, International Journal of Pharmaceutics,2021, 597: 120310.(IF=6.51)

9.Hongyan Zhang^#;Ji Li^#; Rong Yuan; Yufen Li; Yue Zhang; Xiaoyun Hu; Jiqiang Qu; Yu Chen; Zheran Wang*; Mingyu Xia*; Dongkai Wang*; Augment the efficacy of eradicating metastatic lesions and tumor proliferation in breast cancer by honokiol-loaded pH-sensitive targeted lipid nanoparticles, Colloids and Surfaces B: Biointerfaces,2021, 207: 112008.(IF=5.999)

10.Ji Li; Ming Zhao; Meng Sun; Siwen Wu; Hongyan Zhang; Yinghui Dai*; Dongkai Wang*; Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment, ACS Applied Materials & Interfaces,2020, 12(45): 50734-50747.(IF=9.229)